Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study
Eur J Haematol (in press)
DOI 10.1111/ejh.70078, PubMed 41531337
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study
Eur J Haematol (in press)
DOI 10.1111/ejh.70059, PubMed 41486550
Maternal and infant immunity against Bordetella pertussis, Norway, 2020 to 2023
Euro Surveill, 30 (50)
DOI 10.2807/1560-7917.ES.2025.30.50.2500450, PubMed 41414933